<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900887</url>
  </required_header>
  <id_info>
    <org_study_id>HJM 1470/08.03.18</org_study_id>
    <nct_id>NCT00900887</nct_id>
  </id_info>
  <brief_title>Topic Antiinflammatory Therapy Added to Selective Photocoagulation in Macular Edema</brief_title>
  <official_title>Efficacy of Topic Antiinflammatory Therapy Treatment in Center Point Thickness Secondary to Selective Photocoagulation in Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Juarez de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Juarez de Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of ocular topic antiinflammatory
      therapy (sodic nepafenac at 0.1% or ketorolac at 0.5%) to treat center point thickness
      secondary to selective photocoagulation in diabetics with clinically significant macular
      edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Selective photocoagulation is the standard treatment for clinically significant macular
      edema. This treatment decreased the incidence of moderate visual loss in the long term.
      Nonetheless, in the first six weeks after treatment it is induced, probably because an
      exacerbation of macular edema secondary to treatment. An inflammatory response has been
      reported after selective photocoagulation. Therefore, antiinflammatory therapy like ketorolac
      or nepafenac could be useful to manage center point thickness secondary to selective
      photocoagulation in diabetics with macular edema.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ocular topic antiinflammatory therapy (ketorolac, nepafenac or placebo) applied 3 times a day in the treated eye for a week after selective photocoagulation</measure>
    <time_frame>one week after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>center point thickness using stratus OCT measured in microns</measure>
    <time_frame>before treatment, at 24, 48 and 168 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macular volume using stratus OCT measured in cubic millimeters</measure>
    <time_frame>before treatment, 24, 48 and 168 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual capacity under subjective refractive correction measured in decimal equivalent</measure>
    <time_frame>before treatment, at 24, 48, 168 hours after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ocular topic ketorolac used 3 times a day for a week after the selective photocoagulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nepafenac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ocular topic nepafenac 3 times a day during one week after selective photocoagulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polietilenglicol 400, propilenglicol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ocular lubricant drops 3 times a day for a week after selective photocoagulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>ophthalmic presentation 5 mg/ml dosage one drop (0.25 mg) in the treated eye 3 times a day during one week</description>
    <arm_group_label>Ketorolac</arm_group_label>
    <other_name>Godek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepafenac</intervention_name>
    <description>topic presentation 1 mg/ml dosage one drop (0.05 mg) in the treated eye 3 times a day during one week</description>
    <arm_group_label>Nepafenac</arm_group_label>
    <other_name>Nevanac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polietilenglicol 400, propilenglicol</intervention_name>
    <description>ocular presentation Polietilenglicol 400 (4 mg), propilenglicol (3 mg), HP guar (1.9 mg)/1 ml
dosage: one drop (0.2 mg polietinglicol 400, 0.15 mg propilenglicol, 0.095 mg HP guar) 3 times a day during one week</description>
    <arm_group_label>Polietilenglicol 400, propilenglicol</arm_group_label>
    <other_name>Systane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes

          -  regardless of diabetes duration and retinopathy severity level

          -  one or both eyes with focal clinically significant macular edema

          -  treated with selective or focal photocoagulation

          -  visual capacity under subjective refraction before treatment

          -  adequate quality 6mm fast macular map on the day of photocoagulation

          -  signed of inform consent

        Exclusion Criteria:

          -  ocular surgery in the last 4 months

          -  previous selective photocoagulation

          -  topic or systemic antiinflammatory therapy in the last week

          -  allergic to antiinflammatory non-steroids therapy

          -  lent contact used in tha last 2 days before photocoagulation

          -  history of ocular trauma, ocular infection or lacrimal dysfunction in the last 3
             months

          -  history of uveitis or ocular inflammation in the last 12 months

          -  any ocular external disease, infection or inflammatory process during evaluation

          -  corneal abnormalities that could modify visual capacity per se

          -  actual corneal disease

          -  pregnancy

          -  myopia over -6.00 diopters

          -  any retinal disease different from diabetic retinopathy

          -  adverse event of the drug

          -  desert to pharmacology therapy after the second visit

          -  no assistance after the second visit

          -  inadequate quality 6mm fast macular map after the second visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virgilio Lima Gomez, MD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Juarez de Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dulce M Razo Blanco Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Juarez de Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Asbun Bojalil, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Juarez de Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virgilio Lima Gomez</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>07760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Juarez de Mexico</investigator_affiliation>
    <investigator_full_name>Virgilio Lima Gomez</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>diabetic retinopathy</keyword>
  <keyword>clinically significant macular edema</keyword>
  <keyword>selective photocoagulation</keyword>
  <keyword>topic ketorolac</keyword>
  <keyword>topic nepafenac</keyword>
  <keyword>efficacy</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Nepafenac</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

